Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Rent the Runway Inc (RENT) Price & Performance

ACADIA Pharmaceuticals Inc.Trade
Rent the Runway IncTrade

Price performance (Past 24H)

Key statistics

ACADIA Pharmaceuticals Inc. vs Rent the Runway Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while Rent the Runway Inc trades at $3.59 (market cap $122.65M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 41.3× Rent the Runway Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Rent the Runway Inc nearer its low. Which is the better fit depends on your goals.

ACADRENT
Market Cap
$5.07B$122.65M
Sector
HealthConsumer Cyclical
52-Week High
$29.41$9.39
52-Week Low
$20.06$3.01
Enterprise Value
$4.19B$282.75M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

Rent the Runway Inc

Rent the Runway (RENT) trades at $3.60, down 1.1% on the day. The stock shows a bullish technical signal with positive moving averages, while fundamentals reveal a mixed picture: revenue grew to $306.20M in 2025 (company filing, 2025), but net losses persist at -$69.90M. Recent leadership changes, with Teri Bariquit appointed interim CEO (GlobeNewsWire, 2026-05-13), add a layer of transition. The company maintains a high gross margin of 73.81%, yet negative shareholder equity of -$182.50M signals significant financial leverage.

The outlook is cautiously optimistic. A low P/S ratio of 0.2 suggests potential undervaluation if the company can achieve projected profitability in 2026. However, high debt levels, consecutive annual net losses, and execution risks under new leadership pose substantial threats to shareholder value. Analyst sentiment is divided, with a 'Hold' bias reflecting this uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

Read more on ACAD

About Rent the Runway Inc

Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.

Read more on RENT